DiaMedica Therapeutics Inc DMAC

Healthcare Biotechnology

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.

NDAQ:DMAC - Post by User

DiaMedica Therapeutics Inc

Bullboard Posts

Post by nanaimo16on Nov 19, 2014 8:54pm

229 Views

Post# 23146186

DMA Roll-back------------- One new for 20 Old

This is my call.. Rollback at 5c a share. New share is $1.00 Issue 2.5million shares raise $2,500,000.00. Present shareholders are toast. Only way to recover is wait till after roll-back.. let this settle then invest your original amount.

Bullboard Posts

Understanding tax loss season and the “Santa Claus rally”